CRDF
Cardiff Oncology, Inc.
A clinical-stage biotech company developing experimental cancer drugs, headquartered in San Diego. Its lead candidate, onvansertib, is an oral pill being tested against RAS-mutated metastatic colorectal cancer and other hard-to-treat tumors. The company began life in 2002 as a Florida shell company called Used Kar Parts, then rebranded as Xenomics, Trovagene, and finally Cardiff Oncology in 2020, when it set its sights on "turning the tide on cancer."
CUSIP: 8972383091 holder
Total Value
$2.03M
Total Shares
376.1K
Net Share Change
+376.1K
Activity
1 buying
Investor
Value
Shares
Weight
Change
